| Tarceva Side Effect Report | Date Submitted |
|---|---|
| Can't taste a thing | 2011-06-30 |
Tarceva Side Effect Reports Summary
PatientsVille.com - Empowering Patients
Tarceva Studies
Erlotinib in Combination With Pralatrexate in Advanced Malignancies
Erlotinib With or Without Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer With EGFR Mutations
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Ch
Epidermal Growth Factor Receptor-tested Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer
Whole Brain Radiation With or Without Erlotinib for Brain Metastases From Non-Small Cell Lung Cancer
Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable
A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response
Phase I Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)
Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib
A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Ch
Erlotinib Plus ARQ 197 Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER)
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mut
A Study of Tarceva (Erlotinib) Versus Gemcitabine/Cisplatin as First-Line Treatment in Patients With Non-Small Cell Lung Cancer With EGFR Mutations
ARCHER 1009 : A Phase 3 Study Of PF-00299804, A Pan-HER Inhibitor, Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer
A Study of First-line Maintenance Tarceva (Erlotinib) Versus Tarceva at Time of Disease Progression in Patients With Advanced Non-small Cell Lung Cancer After C
A Study of Tarceva (Erlotinib) as First Line Therapy in Patients With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations
Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations
A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Ta
ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Following 4 Cycles of Platinum-Based Chemotherapy With
Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epiderma
A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMA
Trial Evaluating Combined Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma
An Observational Study of Tarceva (Erlotinib) in Routine Practice For First Line Maintenance Therapy in Patients With Non Small Cell Lung Cancer
Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck
Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based C
A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)
Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Patients With Advanced Non-Small Cell Lung Cancer Receiving F
Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia
An Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (TEAM)
A Study of Tarceva (Erlotinib) in Patients With Advanced and/or Metastatic Non-small Cell Lung Cancer With EGFR Positive Mutation (BIOTEC)
Erlotinib in Higher Risk Myelodysplastic Syndrome
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin
Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine o
A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer
Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EG
Erlotinib Prior to Surgery in Patients With Head and Neck Cancer
Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma
A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer
ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
Erlotinib Prevention of Oral Cancer (EPOC)
Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2
Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor
You took Tarceva and now feel unusual symptoms. It could be Tarceva side effect. Help Community - Submit Your Side Effect.
Mobile version
How Did You Deal with Side Effects?About Tarceva : Risks and Benefits, News and Updates, Tarceva video and TV resources<<<<
Tarceva Side Effects Poll. Did You Have a Tarceva Side Effect?<<<<
Tarceva Side Effects - Complete Patient's Guide | User Reviews: Male patient, 75 years of age, took Tarceva |Hair Loss|Skin Rash|Stiff Joints|Dysuria|Constipation ...<<<<
Post Tarceva Side Effect Reporting Your Tarceva side effect will help others recognize and deal with Tarceva side effects. Recent Reports View Tarceva reports ...<<<<
tarceva Episodes: 7: Diagnosed with major depression.Side effects: cardiac failure, myocarditis More: tasigna Episodes: 1: Diagnosed with major depression.Side ...<<<<
tarceva Episodes: 7: Diagnosed with major depression.Side effects: cardiac failure, myocarditis More: telzir Episodes: 1: Diagnosed with major depression.Side ...<<<<
... with co-administration of a single 450 mg dose of TARCEVA on day 8 resulted in a mean erlotinib exposure (AUC) that was 57.6% of that observed following a single ...<<<<
I was looking up TARCEVA (erlotinib) which is a pill used for advanced pancreatic and non-small cell lung cancer patients. It may add some months of survival time in a ...<<<<
An Observational Study of Tarceva (Erlotinib) in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer With Wild-Type Epidermal Growth Factor Rec<<<<